Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of ivabradine modified release versus immediate release in chronic heart failure
2012-001689-13Phase 3Completed
- Sponsor
- Servier
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ivabradine in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Servier. Primary endpoint: Emergent adverse events over 6 months. Started Aug 2012; status: completed.
02
Drugs
ivabradine
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2012-001689-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001689-13.